컨텐츠 바로가기
회사소개
회사연혁
Jennerex
찾아오시는길
핵심기술
SOLVE® 플랫폼
GEEV®플랫폼
논문
파이프라인
파이프라인 개요
펙사벡 (JX-594)
BAL0891
SJ-600 Series
JX-900 Series
파트너십
펙사벡 파트너십
IR/PR
공지 & 뉴스
공고
공시
주가정보
문의하기
자회사소개
신라젠 바이오
찾아오시는 길
신라젠 사이트맵
회사소개
회사연혁
Jennerex
찾아오시는 길
핵심기술
SOLVE® 플랫폼
GEEV®플랫폼
논문
파이프라인
파이프라인 개요
펙사벡 (JX-594)
BAL0891
SJ-600 Series
JX-900 Series
파트너십
펙사벡 파트너십
IR/PR
공지 & 뉴스
공고
공시
주가정보
문의하기
자회사소개
신라젠 바이오
찾아오시는 길
KOR
|
ENG
KOR
KOR
ENG
Targeting, Attacking, and Eradicating Cancers®
TOP
핵심기술
회사소개
핵심기술
파이프라인
파트너십
IR/PR
자회사소개
논문
SOLVE® 플랫폼
GEEV® 플랫폼
논문
논문
총
10
건 ˙
1
/
1
Page
검색어 입력
검색하기 실행 버튼
임상
전임상
리뷰
포스터
Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Mol Ther. 2013 Feb.
NO
10
Phase I Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients with Advanced Solid Cancers.
Mol Ther. 2016 May.
NO
9
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
Mol Ther. 2015 Sep.
NO
8
A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.
Methods Mol Biol. 2015
NO
7
Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.
Mol Ther. 2015 Mar.
NO
6
First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.
Mol Ther. 2015 Jan.
NO
5
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
Nat Med. 2013 Mar.
NO
4
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.
Nature. 2011 Aug.
NO
3
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
Lancet Oncol. 2008 Jun.
NO
2
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma.
Cancer Gene Ther. 1999 Sep.
NO
1
1